US OptionsDetailed Quotes
SRTS250117C2000
- 3.30
- 0.000.00%
15min DelayTrading Jan 17 16:00 ET
0.00High0.00Low
0.00Open3.30Pre Close0 Volume0 Open Interest2.00Strike Price0.00Turnover0.00%IV-24.29%PremiumJan 17, 2025Expiry Date5.00Intrinsic Value100Multiplier-5DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma2.12Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Sensus Healthcare Stock Discussion
Sign in to post a comment
$Sensus Healthcare (SRTS.US)$
Sensus Healthcare Reports Third Quarter 2024 Financial Results With Revenues More than Doubling Versus 2023 Third Quarter
Positive
Revenue increased 127% year-over-year to $8.8 million
Achieved net income of $1.2 million vs net loss of $1.5 million in prior year
Shipped 27 systems vs 11 systems in prior year quarter
Gross profit margin improved to 59.3% from 51.0%
Strong cash position of $22.6 million with no debt
Secured agreement with 130-clinic network Plat...
Sensus Healthcare Reports Third Quarter 2024 Financial Results With Revenues More than Doubling Versus 2023 Third Quarter
Positive
Revenue increased 127% year-over-year to $8.8 million
Achieved net income of $1.2 million vs net loss of $1.5 million in prior year
Shipped 27 systems vs 11 systems in prior year quarter
Gross profit margin improved to 59.3% from 51.0%
Strong cash position of $22.6 million with no debt
Secured agreement with 130-clinic network Plat...
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
$Sensus Healthcare (SRTS.US)$
significantly undervalued company
significantly undervalued company
This patent enhances the company's intellectual property portfolio and reinforces its position as a leader in the dermatological treatment landscape.
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company known for its non-invasive, minimally invasive, and cost-effective treatments for oncological and non-oncological conditions, has unveiled its financial outcomes for the first quarter ended March 31...
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company known for its non-invasive, minimally invasive, and cost-effective treatments for oncological and non-oncological conditions, has unveiled its financial outcomes for the first quarter ended March 31...
No comment yet
Lnova : @Bigmoney Dreamer
EmotionOutofEquation Lnova : Beat my and pro investors expectations keep in close watch may run several days
even weeks 
